Windtree Therapeutics (WINT) said Monday that it regained compliance with Nasdaq's minimum bid price requirements.

The biotech company said it was notified in December that it was out of compliance with the minimum bid price rule because its share price failed to meet a minimum closing price of $1.00 or more for 30 consecutive days.

The company said it will remain under a mandatory panel monitor until March 20, 2026.

Shares of the company were up more than 39% in recent premarket activity.